Study patients
malignant hematologic disease
This research comprised all consecutive adult patients (aged >18 years) with malignant hematologic disease who underwent haplo-HSCT within the period of February 2017 to January 2019 at Wuhan Union Medical College Hospital. All patients who received haplo-HSCT as their initial allogeneic transplant were included in the risk assessment score and outcome analysis. Patients who received a second or third HSCT and those with incomplete medical records were omitted from this work. The flow diagram of the patient is illustrated in Patient flow diagram. HSCT, Hematopoietic Stem Cell Transplantation. AHSCT, Autologous Hematopoietic Stem Cell Transplantation.